Company Update (NASDAQ:AMGN): Phase 3 Pivotal Data On Amgen’s Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology’s 63rd Annual Scientific Session

[PR Newswire] – THOUSAND OAKS, Calif., March 24, 2014 /PRNewswire/ — Amgen (AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational . . . → Read More: Company Update (NASDAQ:AMGN): Phase 3 Pivotal Data On Amgen’s Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology’s 63rd Annual Scientific Session Similar Articles: Amgen Inc. (NASDAQ:AMGN) – Amgen cholesterol drug succeeds in late-stage trial Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Sobi’s partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting Company Update: Amgen Inc. (NASDAQ:AMGN) – Ahead of the Bell: Amgen’s cholesterol drug